Evidence suggests that BRAF inhibitory agents restore RAI uptake in BRAFV600E iodine-refractory thyroid cancer cells, probably by reactivating the expression of thyroid-specific genes involved in iodine metabolism [39]. The gene discussed is BRAF; the disease is thyroid cancer.